Abbott slips after Q1 revenue miss; guidance reaffirmed

Abbott Laboratories (NYSE:ABT) fell ~1% in the early premarket trading on Wednesday after the diagnostics company’s Q1 2025 results fell short of Street forecasts for revenue, despite an earnings beat amid outperformances in its MedTech and Pharma divisions.

However, following in